State Bank of lndia
State Bank of lndia (SBl), the country's largest lender, has raised Rs 4,000 crore of the Basel cgmpliant Additional Tier 1 (AT1) bonds on Wednesday at coupon rate of 7.72 per cent. This is the first AT1 Bond issuance in the domestic market post the new SEBI regulations. The'issue attracted overwhelming response from investors with bids in excess of Rs. 10,000 crores received against a base issue size of Rs. 1,000 crores, which is an indicator of the trust the investors place on the country's largest Bank. This also very clearly demonstrates the maturity of the lndian lnvestors in their selection of lssuers for such instruments.
Based on the response, the Bank has decided to accept Rs. 4,000 crores at a coupo n of 7.72o/o, This is the lowest pricing ever offered on such debt, issued by any lndian bank since the implementation of Basel lll capital rules in 2013. The AT 1 instrument is perpetual in nature, however, it can be called back by the issuer after five years or any anniversary date thereafter
Bajaj Healthcare Limited (BHL) a leading manufacturer of APIs, Intermediates and Formulations has announced the launch of API and Formulation of “DGJAJ” (2-Deoxy-D-Glucose), an antiviral drug used for treating COVID patients, in collaboration with Defence Research and Development Organisation (DRDO). BHL had received a license agreement from DRDO on 7th July, 2021, to manufacture and market 2-Deoxy-D-Glucose (2-DG). The production of “DGJAJ” commenced from today onwards.
2-Deoxy-D-glucose (2-DG) is a glucose analogue, which has the 2-hydroxyl group replaced by hydrogen. 2-DG is transported in cells by the glucose transporters on the cell membrane but it cannot undergo further glycolysis and act as inhibitor of glycolysis. Therefore, cells with higher glucose uptake, for example tumour cells, virally infected cells, inflammatory cells have also a higher uptake of 2-DG. Since, it accumulates selectively more in such cells with high glucose demand; it offers an attractive approach of inhibiting tumour cell growth, viral infection and inflammation.
2-Deoxy-D-Glucose (2-DG) helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence. The drug works by selectively accumulating in the virusinfected cells and prevents virus growth by stopping viral synthesis and energy production. It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe COVID-19 patients as an adjunct therapy to the existing standard of care.
The drug comes in powder form in a sachet, which is taken orally by dissolving it in water. Its selective accumulation in virally infected cells makes this drug unique.
HERO MOTOCORP EXPANDS CUSTOMER TOUCH POINTS & SERVICE CENTERS FOR HARLEY-DAVIDSON RIDERS IN INDIA
BOOKINGS OPEN FOR NEXT LOT OF ‘PAN AMERICA™ 1250’ AFTER THE FIRST BATCH COMPLETELY SOLD OUT
Taking yet another significant step forward in their journey together, Harley-Davidson, the legendary motorcycle brand and Hero MotoCorp, the world’s largest manufacturer of motorcycles and scooters, have expanded the touch points for customers in the country.
Hero MotoCorp now has an expanded network of 14 full-fledged dealerships and seven authorized service centers across the country, exclusively for Harley-Davidson customers
HERO MOTOCORP HANDS OVER 70 MOTORCYCLES AND SCOOTERS TO HARYANA GOVERNMENT FOR FRONT-LINE HEALTH WORKERS
LAUNCHES ‘CORONA WARRIORS ON WHEELS’ IN ASSOCIATION WITH HEALTH DEPARTMENT, HARYANA
In keeping with its commitment towards supporting the COVID-19 relief efforts, Hero MotoCorp Ltd, the world's largest manufacturer of motorcycles and scooters, handed over 70 two-wheelers to Haryana Government at the launch of Project ‘Corona Warriors on Wheels’ here today.
Under the Company’s Corporate Social Responsibility (CSR) platform “Hero WeCare”, Hero MotoCorp handed over 50 units of Hero Xtreme 160R motorcycles and 20 units of Hero Destini 125 scooters to the Director-General of Health Services, Haryana. These vehicles will be allocated to the health workers including doctors and medical staff for community service across the state.
Flagged off by Guest of Honour Dr. Veena Singh, MD, Director General Health Services, Haryana, and Mr. Subhas Sudha, Honorable MLA (Thanesar) - the aim of the initiative is to rapidly expand measures across the state for strengthening their healthcare system and response to COVID-19.
Hero MotoCorp two-wheelers will be used by front-line health workers engaged in COVID-19 related work to provide door-to-door medical services including testing, sanitization, counselling, and mobile vaccination across the city.
Receiving the vehicles, Dr Veena Singh, MD, Director General Health Services, Haryana said “These motorcycles and scooters will prove to be an advantage in our fight against COVID-19 and we are grateful to Hero MotoCorp for extending their support to us. This initiative will go a long way in our fight to stop COVID-19 across the state and widen the scope of our relief activities for the affected people in the district. Helping hands from responsible corporates like Hero MotoCorp helps us to strengthen our mission of bringing relief to the people.”
IndusInd Bank installs rooftop solar panels at Sri Sathya Sai Sanjeevani Hospital in Kharghar, Navi Mumbai
The installation will help the Hospital save close to Rs. 60 lakh, annually towards
energy consumption.
The amount saved, will be used to support 40 cardiac surgeries for children with
heart ailments.
IndusInd Bank today, installed rooftop solar panels at the Sri Sathya Sai Sanjeevani Hospital located at Kharghar, in Navi Mumbai. The installation is a large scale grid solar Photovoltaic system that will generate nearly 300 kilowatt peak (kwp) of energy, thereby reducing carbon emission by over 340 Metric Tonnes. Moreover, it will help the Hospital save nearly Rs. 60 lakh, annually towards energy consumption, which will then be used to facilitate cardiac surgeries of 40 children suffering from congenital heart diseases, free of cost.
Infosys Foundation Inaugurates the Silver Jubilee Block at Sri Ramakrishna Sevashrama, Pavagada
Infosys Foundation, the philanthropic and CSR arm of Infosys (NSE, BSE, NYSE: INFY), today announced the inauguration of the Silver Jubilee Block at Sri Ramakrishna Sevashrama, Pavagada. The Foundation provided a grant of INR 5.5 Crore towards the construction and development of this Block, that will aim to provide the best-in-class Ophthalmology and ENT services, among other healthcare facilities to patients.
The Silver Jubilee Block was inaugurated virtually by Shri. M. Venkaiah Naidu, Hon’ble Vice-President of India.
The grant from Infosys Foundation was utilised to construct this Block which will accommodate special units for eye care, two operating theatres for surgical procedures, a high-tech diagnostic centre, an ENT centre and a cancer clinic. In addition, a part of the grant was also used to procure necessary medical equipment, furniture, computers, and air conditioners required for operation theatres.
This Silver Jubilee Block will aim to facilitate almost 4,000 surgeries and benefit a minimum of 30,000 outpatients every year.
Speaking on the occasion Mrs. Sudha Murty, Chairperson, Infosys Foundation, said, “Infosys Foundation always tries to do its best towards those who are in need. This hospital and its services will aim to help thousands of underprivileged patients in the country. We thank our Hon’ble Vice President Shri. Venkaiah Naidu for gracing this occasion, and convey our best wishes to Sri Ramakrishna Sevashrama, Pavagada.”
Swami Japananda, President of Sri Ramakrishna Sevashrama said, “We are grateful for our continued collaboration with Infosys Foundation. Providing proper treatment to help underprivileged patients receive quality healthcare, will play a big role towards the development of healthcare services in our country. We wholeheartedly thank Infosys Foundation for their unwavering commitment and support in this endeavour.”
This initiative further adds to Infosys Foundation’s efforts to expand hospital and quarantine facilities and ensure proper medical treatment for the public. Over the last one and a half years, Infosys committed a total of INR 200 Crore for Covid relief efforts across India. The Infosys Foundation also set up a 150-bed Covid care hospital in Bengaluru, in partnership with the state government, and recently supported the construction of a 75,000 sq. ft state-of-the-art, multi-disciplinary Outpatient Department (OPD) block at the Kidwai Memorial Institute of Oncology, Bengaluru.
Maruti Suzuki to proactively recall 181,754 units of some petrol variants of Ciaz, Ertiga, Vitara Brezza, S-Cross and XL6
As a responsible corporate, keeping in mind customer safety, Maruti Suzuki India Limited today announced to proactively undertake a recall of some petrol variants of Ciaz, Ertiga, Vitara Brezza, S-Cross and XL6. This is to inspect for a possible defect in 181,754 units of these models manufactured between 4th May 2018 to 27th October 2020.
Recall campaigns are undertaken globally to rectify faults that may be potential safety defects.
In the interest of customers, Maruti Suzuki has decided to voluntarily recall the affected vehicles for inspection/replacement of Motor Generator Unit, free of cost. Affected vehicle owners would be receiving a communication from Maruti Suzuki authorized workshops.
The replacement of the affected part shall start from the first week of November 2021. Till then, customers are requested to avoid driving in water logged areas and direct water spray on electrical/electronic parts in vehicle.
Customers of suspected vehicles can also visit the ‘Imp Customer Info’ section on the Company websites www.marutisuzuki.com (for Ertiga and Vitara Brezza) or www.nexaexperience.com (for Ciaz, XL6 and S-Cross) and fill-in their vehicle’s chassis number (MA3, followed by 14 digit alpha-numeric number) to check if their vehicle needs any attention. The chassis number is embossed on the vehicle ID plate and is also mentioned in the vehicle invoice/registration documents.